NAMS
NewAmsterdam Pharma Company N.V.
$20.23
-1.02
(-4.82%)
Mkt Cap
2.48B
Volume
401,806
52W Range
20.91-42.21
Sector
Healthcare
Beta
0.10
EPS (TTM)
-2.18 USD
P/E Ratio
-20.05
Revenue (TTM)
7.12M USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 22.50M | 45.56M | 14.09M | 102.69M | 0 | 0 |
| Net Income | (203.82M) | (241.60M) | (176.94M) | (22.63M) | (41.78M) | (7.02M) |
| EPS | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 |
| Free Cash Flow | (148.03M) | (159.24M) | (141.24M) | 10.44M | (29.54M) | (7.36M) |
| FCF / Share | -1.29 | -1.69 | -1.72 | 0.55 | -1.66 | -0.41 |
| Operating CF | (147.78M) | (158.56M) | (141.22M) | 10.66M | (29.51M) | (7.34M) |
| Total Assets | 769.28M | 864.62M | 347.10M | 478.50M | 67.99M | 139.87M |
| Total Debt | 202,000 | 448,000 | 60,000 | 126,000 | 186,511 | 0 |
| Cash & Equiv | 490.00M | 771.74M | 340.45M | 467.73M | 60.38M | 1.37M |
| Book Value | 683.43M | 757.50M | 288.39M | 430.07M | 56.63M | 127.46M |
| Return on Equity | -0.30 | -0.32 | -0.61 | -0.05 | -0.74 | -0.06 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.70M | 3.04M | 32,000 | 348,000 | 19.14M | 2.98M | 12.77M | 29.11M | 2.28M | 1.40M | 803,000 | 2.94M |
| Net Income | (64.14M) | (48.44M) | (74.92M) | (72.00M) | (17.36M) | (39.53M) | (92.18M) | (16.65M) | (39.01M) | (93.77M) | (49.49M) | (47.13M) |
| EPS | -0.52 | -0.40 | -0.65 | -0.61 | -0.15 | -0.34 | -0.98 | -0.18 | -0.41 | -1.06 | -0.52 | -0.56 |
| Free Cash Flow | (39.29M) | (30.64M) | (40.98M) | (32.81M) | (37.76M) | (36.48M) | (37.48M) | (12.58M) | (54.19M) | (54.99M) | (33.08M) | (35.33M) |
| FCF / Share | -0.32 | -0.25 | -0.36 | -0.28 | -0.34 | -0.31 | -0.39 | -0.13 | -0.57 | -0.62 | -0.40 | -0.43 |
| Operating CF | (39.21M) | (30.60M) | (40.88M) | (32.77M) | (37.67M) | (36.47M) | (37.48M) | (12.50M) | (53.98M) | (54.60M) | (33.07M) | (35.32M) |
| Total Assets | 704.45M | 732.64M | 769.28M | 786.43M | 815.11M | 818.41M | 864.62M | 439.19M | 446.69M | 488.46M | 347.10M | 0 |
| Total Debt | 82,000 | 23,000 | 202,000 | 266,000 | 328,000 | 389,000 | 448,000 | 506,000 | 562,000 | 43,000 | 60,000 | 0 |
| Cash & Equiv | 424.15M | 457.61M | 490.00M | 538.41M | 563.86M | 748.42M | 771.74M | 422.73M | 430.71M | 481.15M | 340.45M | 418.66M |
| Book Value | 631.42M | 665.22M | 683.43M | 728.07M | 778.50M | 777.36M | 757.50M | 378.86M | 387.44M | 411.80M | 288.39M | 460.99M |
| Return on Equity | -0.10 | -0.07 | -0.11 | -0.10 | -0.02 | -0.05 | -0.12 | -0.04 | -0.10 | -0.23 | -0.17 | -0.10 |
NAMS News
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's Disease
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Analysis
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript